Seroepidemiology of norovirus-associated travelers' diarrhea

Journal of Travel Medicine

Volumn 21, Issue 1, 2014, Pages 6-11

  Ajami, Nadim J ^a,b   Kavanagh, Owen V ^a   Ramani, Sasirekha ^a   Crawford, Sue E ^a   Atmar, Robert L ^a   Jiang, Zhi Dong ^b   Okhuysen, Pablo C ^c   Estes, Mary K ^a   Dupont, Herbert L ^a,b,c,d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d St Luke's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS RNA;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; ENTEROTOXIGENIC ESCHERICHIA COLI; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; NOROVIRUS; NOROVIRUS INFECTION; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROEPIDEMIOLOGY; SEROLOGY; SEROPREVALENCE; TRAVELLER DIARRHEA; VIRUS CHARACTERIZATION; VIRUS DETECTION; VIRUS LIKE AGENT; YOUNG ADULT;

ADULT; DIARRHEA; DISEASE OUTBREAKS; FECES; FEMALE; GASTROENTERITIS; HUMANS; IMMUNOASSAY; IMMUNOGLOBULINS; MALE; MEXICO; NOROVIRUS; OUTCOME ASSESSMENT (HEALTH CARE); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEROEPIDEMIOLOGIC STUDIES; SEROLOGIC TESTS; TRAVEL; UNITED STATES;

EID: 84891802092     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/jtm.12092     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm Rep 2011; 60 (RR-3): 1-18.
2. Zheng DP, Ando T, Fankhauser RL, et al. Norovirus classification and proposed strain nomenclature. Virology 2006; 346: 312-323.
3. Glass RI, Parashar UD, Estes MK,. Norovirus gastroenteritis. N Engl J Med 2009; 361: 1776-1785.
4. Seitz SR, Leon JS, Schwab KJ, et al. Norovirus infectivity in humans and persistence in water. Appl Environ Microbiol 2011; 77: 6884-6888.
5. Wikswo ME, Hall AJ,. Outbreaks of acute gastroenteritis transmitted by person-to-person contact-United States, 2009-2010. MMWR Surveill Summ 2012; 61: 1-12.
6. Ajami N, Koo H, Darkoh C, et al. Characterization of norovirus-associated traveler's diarrhea. Clin Infect Dis 2010; 51: 123-130.
7. Koo HL, Ajami NJ, Jiang ZD, et al. Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico. J Clin Microbiol 2010; 48: 1673-1676.
8. Chapin AR, Carpenter CM, Dudley WC, et al. Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrhea. J Clin Microbiol 2005; 43: 1112-1117.
9. Ko G, Jiang ZD, Okhuysen PC, DuPont HL,. Fecal cytokines and markers of intestinal inflammation in international travelers with diarrhea due to noroviruses. J Med Virol 2006; 78: 825-828.
10. Koo HL, Ajami N, Atmar RL, DuPont HL,. Noroviruses: the leading cause of gastroenteritis worldwide. Discov Med 2010; 10: 61-70.
11. Lindesmith LC, Donaldson EF, Lobue AD, et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 2008; 5: e31.
12. Noel JS, Fankhauser RL, Ando T, et al. Identification of a distinct common strain of "Norwalk-like viruses" having a global distribution. J Infect Dis 1999; 179: 1334-1344.
13. Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB,. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis 1990; 161: 18-21.
14. Parrino TA, Schreiber DS, Trier JS, et al. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med 1977; 297: 86-89.
15. Czako R, Atmar RL, Opekun AR, et al. Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol 2012; 19: 284-287.
16. Nurminen K, Blazevic V, Huhti L, et al. Prevalence of norovirus GII-4 antibodies in Finnish children. J Med Virol 2011; 83: 525-531.
17. Reeck A, Kavanagh O, Estes MK, et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2011; 202: 1212-1218.
18. Jiang ZD, Lowe B, Verenkar MP, et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 2002; 185: 497-502.
19. Anderson AD, Garrett VD, Sobel J, et al. Multistate outbreak of Norwalk-like virus gastroenteritis associated with a common caterer. Am J Epidemiol 2001; 154: 1013-1019.
20. Kojima S, Kageyama T, Fukushi S, et al. Genogroup-specific PCR primers for detection of Norwalk-like viruses. J Virol Methods 2002; 100 (1-2): 107-114.
21. Dupont HL, Jiang ZD, Belkind-Gerson J, et al. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol 2007; 5: 451-456.
22. Kavanagh O, Estes MK, Reeck A, et al. Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. Clin Vaccine Immunol 2011; 18: 1187-1190.
23. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med 2011; 365: 2178-2187.
24. Shah N, DuPont HL, Ramsey DJ,. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg 2009; 80: 609-614.
25. Atmar RL, Estes MK,. Norovirus vaccine development: next steps. Expert Rev Vaccines 2012; 11: 1023-1025.